<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-4085</journal-id>
<journal-title><![CDATA[Revista mexicana de urología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. urol.]]></abbrev-journal-title>
<issn>2007-4085</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-40852023000600007</article-id>
<article-id pub-id-type="doi">10.48193/5ys34h17</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Synchronous Primary Testicular Tumor: a case report of diffuse large B-cell lymphoma]]></article-title>
<article-title xml:lang="es"><![CDATA[Tumor testicular primario sincrónico: reporte de un caso de linfoma difuso de células B grandes]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gilmar Pereira]]></surname>
<given-names><![CDATA[Silva]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vitor Pereira]]></surname>
<given-names><![CDATA[Xavier Grangeiro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Dantas de Oliveira]]></surname>
<given-names><![CDATA[Carmelita Félix]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidade de Brasília  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Brazil</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Sistema Único de Salud del Municipio de João Pessoa  ]]></institution>
<addr-line><![CDATA[ Paraíba]]></addr-line>
<country>Brasil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<volume>83</volume>
<numero>6</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-40852023000600007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-40852023000600007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-40852023000600007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Case description:  63-year-old man of with 7-month history of progressive and gradual increase in testicular size without pain, symptoms of local or systemic infection. Biomarkers for testicular neoplasia were within the reference range: LDH(167 U/L), AFP( 1.49 IU/mL), and HCG( 0.2 mUI/mL). MR): enlarged testicular dimensions showing nodular lesions of heterogeneous enhancement. The patient initially underwent a inguinal orchiectomy who revealed diffuse large B-cell lymphoma.  Relevance:  primary testicular lymphoma (PTL) is a rare non-Hodgkin lymphoma (NHL) that occurs in 1-2% of all cases of NHL and commonly presents as diffuse large B-cell lymphoma in 80-90% of cases. Bilateral and synchronous lesions are observed in 1-2% and 10% of cases, respectively. In this report, we describe our experience regarding this cancer.  Clinical implications:  if not properly conducted, it can end in advanced disease with no prospect of cure, infertility, primary hypogonadism and psychological alterations due to the removal of the gonads.  Conclusions:  PTL is a rare malignancy associated with high recurrence rates and poor prognosis, and multimodal therapy is warranted to achieve better long-term survival and cure rates.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Descripción del caso clínico:  varón de 63 años de edad con antecedentes de aumento de tamaño testicular progresivo y gradual de 7 meses de evolución sin dolor, síntomas de infección local o sistémica. Los biomarcadores de neoplasia testicular estuvieron dentro del rango de referencia: LDH (167 U/L), AFP (1,49 UI/mL) y HCG (0,2 mUI/mL). RM: agrandamiento de las dimensiones testiculares que muestra lesiones nodulares de realce heterogéneo. Inicialmente, el paciente se sometió a una orquiectomía inguinal que reveló un linfoma difuso de células B grandes.  Relevancia:  el linfoma testicular primario es un linfoma no Hodgkin (LNH) poco común que ocurre en el 1-2 % de todos los casos de LNH y comúnmente se presenta como un linfoma difuso de células B grandes en el 80-90% de los casos. Se observan lesiones bilaterales y sincrónicas en el 1-2% y el 10% de los casos, respectivamente. En este informe, describimos nuestra experiencia con respecto a este cáncer.  Implicaciones clínicas:  si no se realiza correctamente, puede terminar en enfermedad avanzada sin posibilidad de curación, infertilidad, hipogonadismo primario y alteraciones psicológicas por la extirpación de las gónadas.  Conclusiones:  el linfoma testicular primario es una neoplasia maligna rara asociada con altas tasas de recurrencia y mal pronóstico, y la terapia multimodal está justificada para lograr mejores tasas de curación y supervivencia a largo plazo.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Primary testicular lymphoma]]></kwd>
<kwd lng="en"><![CDATA[diffuse large-B cell lymphoma]]></kwd>
<kwd lng="en"><![CDATA[orchiectomy]]></kwd>
<kwd lng="en"><![CDATA[testis cancer]]></kwd>
<kwd lng="en"><![CDATA[testicular chemotherapy]]></kwd>
<kwd lng="es"><![CDATA[Linfoma testicular primario]]></kwd>
<kwd lng="es"><![CDATA[linfoma difuso de células B grandes]]></kwd>
<kwd lng="es"><![CDATA[orquiectomía]]></kwd>
<kwd lng="es"><![CDATA[cáncer de testículo]]></kwd>
<kwd lng="es"><![CDATA[quimioterapia testicular]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laguna]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Albers]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Algabara]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bokemeyer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Boormans J]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fischer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[EUA Guidelines on Testicular Cancer]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sia]]></surname>
<given-names><![CDATA[NPX]]></given-names>
</name>
<name>
<surname><![CDATA[Chekrine]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bourhafour]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ouadii]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bouchbika]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Benchakroun]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary Testicular Lymphoma: A Case Report and Review of the Literature]]></article-title>
<source><![CDATA[Journal of Cancer Therapy]]></source>
<year>2022</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>145-54</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campobasso]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ferretti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Frattini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Synchronous bilateral testis cancer: clinical and oncological management]]></article-title>
<source><![CDATA[Contemporary Oncology]]></source>
<year>2017</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>70-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Lorca Álvaro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Carretero del Barrio]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Laso García]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[García Cosío]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mata Alcaraz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary testicular lymphoma: Clinical characteristics and oncological outcomes]]></article-title>
<source><![CDATA[Current Urology]]></source>
<year>2023</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>130-4</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rossi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Orecchioni]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Falvo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Tabanelli]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Baiardi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Agostinelli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma]]></article-title>
<source><![CDATA[Leukemia]]></source>
<year>2022</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>197-209</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Bao]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chai]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and validation of a survival nomogram in patients with primary testicular diffuse large B-cell lymphoma]]></article-title>
<source><![CDATA[The Journal of International Medical Research]]></source>
<year>2023</year>
<volume>51</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>3000605231197052</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shing Oh]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Prajapati]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mahalingam]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diffuse large B-cell lymphoma of the skin and testis: A diagnostic and staging dilemma]]></article-title>
<source><![CDATA[Indian Journal of Dermatology, Venereology and Leprology]]></source>
<year>2023</year>
<volume>89</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>79-81</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Unusually aggressive primary testicular diffuse large B-cell lymphoma initially presenting as systemic disseminating metastases in older adult men: a case report]]></article-title>
<source><![CDATA[Annals of Medicine and Surgery]]></source>
<year>2012</year>
<volume>85</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>4106-11</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sehn]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Salles]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diffuse Large B-Cell Lymphoma]]></article-title>
<source><![CDATA[The New England Journal of Medicine]]></source>
<year>2021</year>
<volume>384</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>842-58</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trama]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Illiano]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Aveta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pandolfo]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Bertuzzi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Costantini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bilateral Primary testicular diffuse large B-CELL lymphoma]]></article-title>
<source><![CDATA[Urology Case Reports]]></source>
<year>2021</year>
<volume>38</volume>
<page-range>101733</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Shaik]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Negi]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Rajguru]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Patil]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
<name>
<surname><![CDATA[Parihar]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-Hodgkin&#8217;s lymphoma: A review]]></article-title>
<source><![CDATA[Journal of Family Medicine and Primary Care]]></source>
<year>2020</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1834-40</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orellana-Noia]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Abousaud]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies]]></article-title>
<source><![CDATA[Current Treatment Options in Oncology]]></source>
<year>2022</year>
<volume>23</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1443-56</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Goodlad]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Calaminici]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dotlic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Montes-Moreno]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Oschlies]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis]]></article-title>
<source><![CDATA[Virchows Archiv: An International Journal of Pathology]]></source>
<year>2020</year>
<volume>476</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>647-65</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spinner]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Advani]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current Frontline Treatment of Diffuse Large B-Cell Lymphoma]]></article-title>
<source><![CDATA[Oncology (Williston Park, N.Y.)]]></source>
<year>2022</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>51-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schepisi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[De Padova]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[De Lisi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Casadei]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Meggiolaro]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ruffilli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psychosocial Issues in Long-Term Survivors of Testicular Cancer]]></article-title>
<source><![CDATA[Frontiers in Endocrinology]]></source>
<year>2019</year>
<volume>10</volume>
<page-range>113</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elenkov]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Giwercman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Testicular Dysfunction Among Cancer Survivors]]></article-title>
<source><![CDATA[Endocrinology and metabolism clinics of North America]]></source>
<year>2022</year>
<volume>51</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
